RSE Welcomes New Enterprise Fellows

The RSE are delighted to welcome the next cohort of Enterprise Fellows into the programme. There are seven aspiring entrepreneurial individuals from six institutions, with innovative ideas for businesses that range from drug discovery, food and drink, to equestrian sporting equipment. Meet our newest Enterprise Fellows below:


Selby Cary, Research & Enterprise Services, Heriot-Watt University
Casta Spes Technologies (CST) – The MANTIS Project

CST is developing a new ground-based remote control vehicle, called the MANTIS, which has the manoeuvrability of a of a drone and accessibility of a traditional radio control (RC) car. The MANTIS succeeds where conventional RC cars and drones struggle; uneven surfaces and low altitude respectively, creating a new market for high performance land drones.

The MANTIS comprises of a self-stabilising mechanism and camera attachment for users to capture unforgettable moments for a characteristic viewpoint. The all-terrain capabilities, extended battery life, ease of use and distinctive user experience are the unique selling points.

This gap in the market will be exploited commercially using an engaging and exciting marketing campaign. The MANTIS will be marketed to adventure seekers, such as mountain bikers and hikers, and hobbyists that enjoy the use of leisure vehicles. Future applications could see the MANTIS utilised in delivery operations, cinematography, scouting missions, military or even search and rescue activities.


Carmen Cummiskey, DMEM, University of Strathclyde
TEQNOX Equestrian Body Protection

Teqnox Limited is an innovate start up company that designs body protection for equestrian sport. It was founded by Director Carmen Cummiskey after it was identified that current body protection was bulky, restrictive and often difficult to get on.

There are 3 million horse riders in the UK alone each of which would benefit from the use of a body protector. Indirect spending on equestrian items such as hats and body protectors has seen steady growth since 2011 growing from £557 Million to £560 Million over a four-year period.

Our aim is to build an innovative equestrian sport brand in an industry that is lacking innovation and eye catching digital marketing. We will be utilising brand ambassadors and have already created an exciting new ecommerce ready webpage that we will drive traffic through to our respective online ambassadors and blogs.


Ifeyinwa Kanu, Environmental Engineering, Heriot-Watt University
A novel ultra-small scale anaerobic food waste digester

If food waste were a country, it would be the third largest emitter of greenhouse gas following United States of America and China. In the UK we only manage to recycle 43-44% of our food waste, leaving over 6 million tonnes to rot. Thus, there is a gap (People lack motivation to recycle) in the market that has remained untapped by the existing industrial-scale centralised food waste recycling plants. We have developed a small-scale food waste recycler that lets clients treat food waste, and generate energy, on their premises which they use thereby committing them to recycle more efficiently.

We have approached and worked with a number of major producers of food waste, organisations who incur considerable inconvenience and costs in removing that waste. These include NHS Highland, Nestle-UK, Nourish Scotland and Costain. One comment from a major potential customer was ‘We can see that … everyone will want one of these’.


Anna Lito Michala, School of Computing Science, University of Glasgow
Clydesope Health Ltd; 1st Product to Market: HypoRes-Q

The proposition is designing a solution for reconstitution of drugs that provides a broad and substantial patent for use in wearable medical devices. The technology will initially be applied to Diabetes applications and the business will be exploring the 15 additional market applications that were identified when developing the concept.

There is a clear gap in the market for a solution to hypoglycaemia in diabetic patient that is less cumbersome and reliant on third party intervention, than current existing emergency treatments. All the current solutions in development do not address the need for third party intervention and will always require a first aider to administer the solution.

After engaging with patients, manufactures and doctors alike we have received significant positive feedback to develop a solution for Hypoglycaemia. At present, we have prototyped a solution that meets the market needs and are looking to commercialise it through licencing.


Isatou Njai, Health & Life Sciences, Glasgow Caledonian University
Drink Baotic: Functional Health Drink for the UK Market

My company, Hippo & Hedgehog, innovates African ingredients to UK taste preferences. Our aim is to promote the vibrancy of Africa, through healthy diets and happy and helpful lives.

Baotic is a dairy-free, high fibre, prebiotic functional health drink made from the Baobab super fruit. It is rich in vitamins and minerals, high in soluble and insoluble fibre, and beneficial for digestive health. In combining pure baobab with orange, banana and strawberry, our drinks are deliciously fruity in taste, with a unique sherbet kick. They are green on the whole traffic light system; zero fat, zero salt, 3% natural sugar and low calorie. These drinks are also vegan, gluten free and soy free, catering for many dietary and lifestyle requirements.

Our Mission: To inspire and empower healthy communities around the world.

Our Vision: To be the number-one-trusted African inspired food and beverage brand promoting health and convenience.


Kate Cameron, Edinburgh Innovations, The University of Edinburgh
Automated high throughput screening for toxicology testing.

Drug discovery is slow, expensive and unreliable.

The cost of developing a single new drug takes over a decade, more than $1.8 billion, using a process where 97% of drugs fail. This rate of attrition is too high, over 50% of acute failures are attributed to Drug Induced Liver Injury (DILI) which caused by poor, inaccurate models that do not predict toxicity.

Cytochroma propose a solution to this by generating stable, scalable, reliable, DILI predictive human liver cells (hepatocytes) in a rapid, cheap, sensitive screening method, to accurately identify toxicity.

Our drug screening platform can screen commercially relevant numbers of compounds at an attractive, cost effective price. By failing faster, drugs fail cheaply – pharmaceutical and biotech companies can save significantly, reducing the cost of one drug by up to $30 million and increasing launch rate by 25%.


Benjamin Carter, School of Cellular and Molecular Medicine, University of Bristol

We at the Perriman group from the University of Bristol have developed a ‘cell painting’ technology that offers the ability to incorporate virtually any protein into virtually any cell membrane. We are developing this system to introduce homing capacity into stem cells, presenting a solution to major barriers for cell therapies including targeting and cell retention.

Through CytoSeek, we aim to bring targeted cell therapies to a commercial reality. The first application of this disruptive patent-pending technology will be to home stem cells to damaged heart tissue to aid the treatment of cardiovascular disease (CVD), the world’s number one cause of death.

CytoSeek’s customers will be the rapidly growing list of cell therapy companies as well as pharmaceutical multinationals looking to break into the rapidly growing biologics market.